enGene (NASDAQ:ENGN – Get Free Report) is one of 445 public companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare enGene to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Profitability
This table compares enGene and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
enGene | N/A | -63.25% | -5.65% |
enGene Competitors | -11,569.27% | -124.49% | -24.30% |
Dividends
enGene pays an annual dividend of $1.58 per share and has a dividend yield of 26.0%. enGene pays out -97.0% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 3.1% and pay out 5,578.4% of their earnings in the form of a dividend. enGene is clearly a better dividend stock than its peers, given its higher yield and lower payout ratio.
Earnings & Valuation
Gross Revenue | Net Income | Price/Earnings Ratio | |
enGene | N/A | $104.74 million | -3.74 |
enGene Competitors | $160.50 million | -$18.86 million | 76.89 |
enGene’s peers have higher revenue, but lower earnings than enGene. enGene is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a breakdown of current recommendations and price targets for enGene and its peers, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
enGene | 0 | 0 | 6 | 0 | 3.00 |
enGene Competitors | 751 | 2451 | 5754 | 67 | 2.57 |
enGene presently has a consensus target price of $34.40, suggesting a potential upside of 464.86%. As a group, “Biotechnology” companies have a potential upside of 15.94%. Given enGene’s stronger consensus rating and higher possible upside, research analysts clearly believe enGene is more favorable than its peers.
Volatility & Risk
enGene has a beta of -0.63, indicating that its stock price is 163% less volatile than the S&P 500. Comparatively, enGene’s peers have a beta of 1.23, indicating that their average stock price is 23% more volatile than the S&P 500.
Institutional and Insider Ownership
64.2% of enGene shares are owned by institutional investors. Comparatively, 31.2% of shares of all “Biotechnology” companies are owned by institutional investors. 13.7% of enGene shares are owned by insiders. Comparatively, 22.4% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Summary
enGene beats its peers on 10 of the 15 factors compared.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.